SOURCE-LINKED INTELLIGENCE

AI-powered platform for autologous iPSC manufacturing

CORDIS · observation · Publication date unknown

ss production of personalized iPSCs for autologous adoptive cancer immunotherapies, hematopoietic stem cell transplantation, and tissue regeneration. The consortium will for the first time create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs fast and at a fraction of the current cost. Moreover, it will conduct cutting-edge single cell genomics and bioinformatics research of iPSC to identify clones of highest quality, and develop a database that will be the basis for AI software to select clones that meet clinical standards. The consortium comprises of experts in microfluidics engineering process automation for cell therapies, stem cell molecular biology and bioinformatics, GMP production, and AI modelling. The participating companies, startups, and universities are amongst the leading in Europe, and will promote the positions of female and early career participants from developed and developing European countries. The consortium aims to reach TRL3 prototype stage, and have created a concrete exploitation plan to

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

3999225

unit

EUR